JPS58128325A - プロスタグランジンｅ類を含む安定な薬剤組成物およびその製造法 - Google Patents

プロスタグランジンｅ類を含む安定な薬剤組成物およびその製造法

Info

Publication number
JPS58128325A
JPS58128325A JP58006747A JP674783A JPS58128325A JP S58128325 A JPS58128325 A JP S58128325A JP 58006747 A JP58006747 A JP 58006747A JP 674783 A JP674783 A JP 674783A JP S58128325 A JPS58128325 A JP S58128325A
Authority
JP
Japan
Prior art keywords
pge
compounds
hydrogen
solvent
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58006747A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0460973B2 (enExample
Inventor
チエン−ダ−・ユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of JPS58128325A publication Critical patent/JPS58128325A/ja
Publication of JPH0460973B2 publication Critical patent/JPH0460973B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
JP58006747A 1982-01-21 1983-01-20 プロスタグランジンｅ類を含む安定な薬剤組成物およびその製造法 Granted JPS58128325A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/341,403 US4409239A (en) 1982-01-21 1982-01-21 Propylene glycol diester solutions of PGE-type compounds
US341403 1982-01-21

Publications (2)

Publication Number Publication Date
JPS58128325A true JPS58128325A (ja) 1983-07-30
JPH0460973B2 JPH0460973B2 (enExample) 1992-09-29

Family

ID=23337403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58006747A Granted JPS58128325A (ja) 1982-01-21 1983-01-20 プロスタグランジンｅ類を含む安定な薬剤組成物およびその製造法

Country Status (11)

Country Link
US (1) US4409239A (enExample)
EP (1) EP0084865B1 (enExample)
JP (1) JPS58128325A (enExample)
AU (1) AU555082B2 (enExample)
CA (1) CA1203172A (enExample)
DE (1) DE3366835D1 (enExample)
HK (1) HK3288A (enExample)
IE (1) IE54530B1 (enExample)
NZ (1) NZ203061A (enExample)
SG (1) SG81587G (enExample)
ZA (1) ZA83395B (enExample)

Families Citing this family (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515810A (en) * 1983-10-06 1985-05-07 American Cyanamid Company Composition of matter
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5004651A (en) * 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
AU645070B2 (en) * 1990-04-10 1994-01-06 Nb International Technologies Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US7169410B1 (en) 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
EP1465882B1 (en) * 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Hetrocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
EP1606291A2 (en) 2002-07-02 2005-12-21 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its dervatives
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
WO2004110350A2 (en) * 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
ES2332135T3 (es) * 2003-06-03 2010-01-27 Novartis Ag Inhibidores p-38 basados en heterociclo de 5 miembros.
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
EP1911754B1 (en) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050203184A1 (en) 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
US7470798B2 (en) 2003-09-19 2008-12-30 Edison Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2005113523A1 (en) 2004-05-20 2005-12-01 Foldrx Pharmaceuticals, Inc. 2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
EP1786421A2 (en) * 2004-07-09 2007-05-23 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
US20100190688A1 (en) 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
US20060034978A1 (en) * 2004-08-16 2006-02-16 Grain Processing Corporation Aerosol compositions, devices and methods
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
CA2580767A1 (en) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006130217A2 (en) * 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
WO2007073398A2 (en) 2005-05-23 2007-06-28 Natural Alternatives International Compositions and methods for the sustained release of beta-alanine
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
KR20080102200A (ko) * 2006-03-13 2008-11-24 엔싸이시브 파마슈티칼즈 인코퍼레이티드 시탁센탄 나트륨의 제제
WO2007106537A2 (en) 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones as gsk-3 inhibitors
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
EA200870385A1 (ru) * 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
CA2664152C (en) 2006-09-21 2014-09-30 Activx Biosciences, Inc. Serine hydrolase inhibitors
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2666138A1 (en) 2006-10-09 2008-05-08 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2008051502A1 (en) 2006-10-19 2008-05-02 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
BRPI0715579A2 (pt) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
JP2010508307A (ja) 2006-10-31 2010-03-18 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
AU2008219622A1 (en) 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
LT2125698T (lt) 2007-03-15 2016-10-10 Auspex Pharmaceuticals, Inc. Deuterintas d9-venlafaksinas
EP2170062A4 (en) * 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES
WO2009035634A2 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
MX2010003249A (es) 2007-09-25 2010-11-09 Takeda Pharmaceutical Inhibidores de quinasas símil polo.
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CA2696807C (en) 2007-11-08 2017-11-28 Ambit Biosciences Corp. Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
ES2413504T3 (es) 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
KR101713501B1 (ko) 2008-03-17 2017-03-07 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
RU2010151944A (ru) * 2008-05-20 2012-06-27 Серенис Терапьютикс С.А. (Fr) Ниацин и нспвс для комбинированной терапии
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
EP3064217B1 (en) 2009-01-06 2018-04-18 Galenagen, LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
GB2480773B (en) 2009-01-06 2013-12-11 Curelon Llc Compositions for the treatment of diarrhea caused by virulent E. coli infections
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
RU2529019C2 (ru) 2009-02-27 2014-09-27 Эмбит Байосайенсиз Корпорейшн Модулирующие jak киназу хиназолиновые производные и способы их применения
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
MX2011009989A (es) 2009-03-23 2011-10-14 Ambit Biosciences Corp Metodos de tratamiento utilizando terapia de combinacion.
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
WO2010111626A2 (en) 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
KR20120034627A (ko) 2009-04-22 2012-04-12 액시킨 파마수티컬스 인코포레이티드 아릴설폰아마이드 ｃｃｒ3 길항제
NZ620048A (en) 2009-04-22 2015-07-31 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
BRPI1014669A2 (pt) 2009-04-22 2017-07-18 Axikin Pharmaceuticals Inc antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DK2451435T4 (da) 2009-07-08 2022-02-28 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Natriumthiosulfat-indeholdende farmaceutiske sammensætninger
US8541417B2 (en) 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
EP2464349A2 (en) 2009-08-14 2012-06-20 Cerenis Therapeutics S.A. Use of ppar delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
US8940790B2 (en) * 2009-11-03 2015-01-27 Bernard Charles Sherman Stable pharmaceutical formulations comprising lubiprostone
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181896A1 (en) * 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
WO2011079778A1 (en) * 2009-12-30 2011-07-07 China Shanghai Fochon Pharmaceutical Co Ltd 3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazine derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8741894B2 (en) 2010-03-17 2014-06-03 Axikin Pharmaceuticals, Inc. Arylsulfonamide CCR3 antagonists
US9408831B2 (en) 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
JP5844354B2 (ja) 2010-06-01 2016-01-13 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
US20130178503A1 (en) 2010-06-01 2013-07-11 Biotheryx Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
EP2576532B1 (en) 2010-06-07 2018-07-18 Novomedix, LLC Furanyl compounds and the use thereof
EP2585455B1 (en) 2010-06-24 2019-08-07 The Regents of the University of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611796B1 (en) 2010-09-01 2016-04-20 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
JP5872558B2 (ja) 2010-09-01 2016-03-01 アムビト ビオスシエンセス コルポラチオン ピラゾリルアミノキナゾリンの臭化水素酸塩
CA2810024A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US20130225615A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US20120088769A1 (en) 2010-10-11 2012-04-12 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
JP6042406B2 (ja) 2011-03-28 2016-12-14 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
BR112013024909A2 (pt) 2011-03-28 2019-09-24 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
EP2691388A1 (en) 2011-03-28 2014-02-05 MEI Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP3305317B1 (en) 2011-04-21 2020-06-24 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
RU2013158449A (ru) 2011-06-23 2015-07-27 Мэп Фармасьютикалс, Инк. Новые фторэрголиновые аналоги
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
CN107982270A (zh) 2011-09-02 2018-05-04 辛达克斯制药股份有限公司 治疗乳腺癌的方法
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
AU2012312308B2 (en) 2011-09-23 2015-11-19 Celgene Corporation Romidepsin and 5-azacitidine for use in treating lymphoma
CN104039330A (zh) 2011-09-26 2014-09-10 细胞基因公司 化疗耐药性的癌症的联合治疗
BR112014010417A2 (pt) 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
EP2793580A4 (en) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc NEW DERIVATIVES OF ISO-ERGOLINE
AU2012355983A1 (en) 2011-12-21 2015-01-22 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2013148919A1 (en) 2012-03-30 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Treatment of multiple myeloma
CN104520268B (zh) 2012-05-02 2017-05-24 勃林格殷格翰国际有限公司 Ssao的取代的3‑卤代烯丙基胺抑制剂及其用途
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (en) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US8551535B1 (en) 2012-08-06 2013-10-08 Sarah McCann Homeopathic remedies and methods for enhancing weight loss
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
KR20150053906A (ko) 2012-09-07 2015-05-19 액시킨 파마수티컬스 인코포레이티드 동위원소 농축 아릴설폰아미드 ccr3 길항제
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
EP2916830A2 (en) 2012-11-08 2015-09-16 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US9156781B2 (en) 2012-11-30 2015-10-13 Novomedix, Llc Substituted biaryl sulfonamides and the use thereof
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
US8895743B2 (en) 2012-12-21 2014-11-25 Map Pharmaceuticals, Inc. Methysergide derivatives
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
AU2014218666B2 (en) 2013-02-22 2018-11-01 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
EP2967049B1 (en) 2013-03-15 2020-09-02 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
JP6462659B2 (ja) 2013-03-15 2019-01-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 非環式ヌクレオシドホスホン酸ジエステル
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
SG11201509982UA (enExample) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2015090235A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US10202398B2 (en) 2014-03-20 2019-02-12 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
US10005765B2 (en) 2014-03-20 2018-06-26 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
WO2015148868A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
AU2015259471A1 (en) 2014-05-12 2016-11-24 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2015195786A2 (en) 2014-06-17 2015-12-23 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
CN112898345A (zh) 2014-09-15 2021-06-04 加利福尼亚大学董事会 核苷酸类似物
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
US10472346B2 (en) 2014-10-31 2019-11-12 The General Hospital Corporation Potent gamma-secretase modulators
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kináz inhibitorok
BR112017015487A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo
CN107405346A (zh) 2015-01-20 2017-11-28 Xoc制药股份有限公司 异麦角灵化合物及其用途
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
BR112017020002A2 (en) 2015-03-20 2018-06-19 Syndax Pharmaceuticals, Inc. COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
CN113713108A (zh) 2015-06-23 2021-11-30 纽罗克里生物科学有限公司 用于治疗神经学疾病或病症的vmat2抑制剂
CN107787373B (zh) 2015-08-17 2021-11-26 库拉肿瘤学公司 法尼基转移酶抑制剂在制备用于治疗癌症的药物中的用途
MX2018002640A (es) 2015-09-02 2018-06-20 Syndax Pharmaceuticals Inc Seleccion de pacientes para la terapia de combinacion.
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
EP3353214B1 (en) 2015-09-25 2021-08-18 Universität Duisburg-Essen Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
LT3875459T (lt) 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP4455145A3 (en) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
KR20180099712A (ko) 2016-01-08 2018-09-05 셀진 코포레이션 항증식성 화합물, 및 이의 약제학적 조성물 및 용도
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019513151A (ja) 2016-03-08 2019-05-23 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． カンプトテシン誘導体及びその使用
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
CN108884019A (zh) 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
WO2017194789A1 (en) 2016-05-13 2017-11-16 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
HUE053927T2 (hu) 2016-11-03 2021-07-28 Kura Oncology Inc Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
WO2018089427A1 (en) 2016-11-09 2018-05-17 Novomedix, Llc Nitrite salts of 1, 1-dimethylbiguanide, pharmaceutical compositions, and methods of use
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US10799503B2 (en) 2016-12-01 2020-10-13 Ignyta, Inc. Methods for the treatment of cancer
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
CN110381960A (zh) 2017-02-02 2019-10-25 麦克马斯特大学 作为抗微生物剂的增强剂的碳酸氢盐
NZ797281A (en) 2017-02-17 2025-10-31 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3432883B1 (en) 2017-02-21 2021-07-28 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
KR102378845B1 (ko) 2017-03-30 2022-03-24 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
WO2018195727A1 (en) 2017-04-24 2018-11-01 Tsinghua University Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
AU2018313738B2 (en) 2017-08-07 2024-07-04 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019033330A1 (en) 2017-08-17 2019-02-21 Xw Laboratories, Inc. PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
EP3988561B1 (en) 2017-09-04 2023-06-07 XWPharma Ltd. Preparation and use of reactive oxygen species scavenger
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
EP3691658A4 (en) 2017-10-04 2021-06-23 The Regents of The University of California IMMUNOMODULATOR OLIGOSACCHARIDES
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
WO2019099353A1 (en) 2017-11-15 2019-05-23 California State University Northridge Compositions and methods for the treatment and prevention of cancer
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
JP7395480B2 (ja) 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
RU2756512C1 (ru) 2018-01-10 2021-10-01 ЭксДабл-ЮФАРМА ЛТД. Пролекарства кетамина, его композиции и применения
AU2019219678A1 (en) 2018-02-08 2020-08-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use
KR20200135996A (ko) 2018-03-23 2020-12-04 에이도스 테라퓨틱스, 인코포레이티드 Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
CN112423747A (zh) 2018-04-27 2021-02-26 云杉生物科学公司 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法
CN121015865A (zh) 2018-05-07 2025-11-28 赛达克斯制药股份有限公司 用于组合疗法的患者的选择
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CN118994395A (zh) 2018-07-20 2024-11-22 皮埃尔法布雷医药公司 Vista受体
WO2020019247A1 (en) 2018-07-26 2020-01-30 Xw Laboratories, Inc. Compounds as neurokinin-1 receptor antagonists and uses thereof
WO2020024060A1 (en) 2018-08-01 2020-02-06 Mcmaster University Methods for inhibiting microbe growth
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
EP4647068A2 (en) 2018-08-17 2025-11-12 Eidos Therapeutics, Inc. Formulations of ag10
CN112004802B (zh) 2018-09-30 2021-12-28 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
US20220002396A1 (en) 2018-11-01 2022-01-06 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
CN113365630A (zh) 2018-12-21 2021-09-07 库拉肿瘤学公司 用于鳞状细胞癌的疗法
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
ES2988904T3 (es) 2019-03-07 2024-11-22 Nobo Medicine Inc Inhibidores de caspasa y métodos de utilización de los mismos
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3946338B1 (en) 2019-03-29 2025-06-18 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
BR112021020864A2 (pt) 2019-04-19 2021-12-14 Ligand Pharm Inc Formas cristalinas e métodos de produção de formas cristalinas de um composto
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CN119752217A (zh) 2019-05-20 2025-04-04 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
ES3036313T3 (en) 2019-05-20 2025-09-17 Nirvana Sciences Inc Narrow emission dyes, compositions comprising same, and methods for making and using same
IL288547B2 (en) 2019-06-03 2025-10-01 Biotheryx Inc Non-hygroscopic crystalline pyrazole compound salts, pharmaceutical preparations thereof and use thereof
US20220274922A1 (en) 2019-07-11 2022-09-01 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications
EP3996813A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
ES2991100T3 (es) 2019-07-26 2024-12-02 Espervita Therapeutics Inc Acidos monocarboxílicos y dicarboxílicos de hidrocarburos de cadena larga funcionalizados útiles para la prevención o el tratamiento de enfermedades
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2021055376A1 (en) 2019-09-16 2021-03-25 Dice Alpha, Inc. Il-17a modulators and uses thereof
WO2021059023A1 (en) 2019-09-26 2021-04-01 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3128410A1 (en) 2019-10-11 2021-04-15 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ws-635 uses thereof in medicine
WO2021092262A1 (en) 2019-11-05 2021-05-14 Dermira, Inc. Mrgprx2 antagonists and uses thereof
WO2021092264A1 (en) 2019-11-05 2021-05-14 Dermira, Inc. MrgprX2 ANTAGONISTS AND USES THEREOF
CN114845709B (zh) 2019-11-05 2024-10-01 德米拉公司 用于治疗炎性病症的mrgprx2拮抗剂
TW202136237A (zh) 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
TW202136238A (zh) 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP4171541A1 (en) 2020-06-24 2023-05-03 NeuroBo Pharmaceuticals, Inc. Gemcabene for treatment of cytokine storms and viral-induced inflammation
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
CN113861185B (zh) 2020-06-30 2023-04-07 广东东阳光药业有限公司 2-(取代的嘧啶基)噻唑甲酰胺化合物的盐及其组合物和用途
US20240317681A1 (en) 2020-07-07 2024-09-26 Sunshine Lake Pharma Co., Ltd. Pyrrolidine amide derivative salt and use thereof
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
KR20230157936A (ko) 2020-12-14 2023-11-17 바이오테릭스, 인코포레이티드 Pde4 분해인자, 약제학적 조성물, 및 치료학적 적용
CN116829136A (zh) 2020-12-16 2023-09-29 生物医学影响公司 菲卓替尼的给药
US20240124483A1 (en) 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022192545A1 (en) 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
CA3222240A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240358722A1 (en) 2021-09-14 2024-10-31 Impact Biomedicines, Inc. Methods of administering fedratinib
CA3236150A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
TW202327590A (zh) 2021-11-30 2023-07-16 美商庫拉腫瘤技術股份有限公司 大環化合物及組合物以及其製備及使用方法
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
CN118922189A (zh) 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US12187699B2 (en) 2022-04-14 2025-01-07 Bristol-Myers Squibb Company GSPT1 compounds and methods of use of the novel compounds
JP2025516555A (ja) 2022-05-10 2025-05-30 バイオセリックス， インコーポレイテッド Ｃｄｋタンパク質分解因子、医薬組成物、及び治療応用
CA3262284A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences Inc Pharmaceutical compositions and forms for the treatment of human papillomavirus (HPV) infection and HPV-induced neoplasm
IL319458A (en) 2022-09-09 2025-05-01 Innovo Therapeutics Inc Compounds that reduce ck1α and dual ck1α/gspt1
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
EP4608834A1 (en) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025231261A1 (en) 2024-05-01 2025-11-06 Protego Biopharma, Inc. Bicyclic and heterocyclic amide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070456A (en) * 1976-04-05 1978-01-24 American Cyanamid Company Compositions containing dioctyl calcium sulfosuccinate
AU3532978A (en) * 1977-05-02 1979-10-25 Michigan The Regents Of The Un Treating psoriasis
JPS6019734B2 (ja) * 1977-05-12 1985-05-17 三共株式会社 安定なプロスタグランジンｅ類製剤の製法
US4178457A (en) * 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof

Also Published As

Publication number Publication date
CA1203172A (en) 1986-04-15
US4409239A (en) 1983-10-11
AU1066583A (en) 1983-07-28
EP0084865A1 (en) 1983-08-03
EP0084865B1 (en) 1986-10-15
DE3366835D1 (en) 1986-11-20
IE54530B1 (en) 1989-11-08
HK3288A (en) 1988-01-22
JPH0460973B2 (enExample) 1992-09-29
IE830114L (en) 1983-07-21
NZ203061A (en) 1985-08-30
AU555082B2 (en) 1986-09-11
ZA83395B (en) 1984-09-26
SG81587G (en) 1988-09-30

Similar Documents

Publication Publication Date Title
JPS58128325A (ja) プロスタグランジンｅ類を含む安定な薬剤組成物およびその製造法
US4328245A (en) Carbonate diester solutions of PGE-type compounds
US4410545A (en) Carbonate diester solutions of PGE-type compounds
US4358603A (en) Acetal stabilized prostaglandin compositions
US3903297A (en) Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
DE69511181T2 (de) Mittel für Behandlung der Leber-Gallenerkrankungen
CA1176567A (en) Pharmaceutical preparation
EP0345951A1 (en) Tracheobronchodilator
CA1216793A (en) Pge-type compositions encapsulated by acid isolated gelatin
JPS6020365B2 (ja) 組成物
US4211793A (en) Triethyl citrate solutions of PGE-type compounds
FI99080C (fi) Menetelmä ruoansulatuskanavan ulkopuoliseen annosteluun tarkoitettujen emulsioiden valmistamiseksi
JPH04243827A (ja) プロスタグランジン誘導体含有溶解型軟膏剤
JPH06507161A (ja) 脂質吸収不良の治療用経腸医薬製剤の製造のための脂質の使用
KR880001561A (ko) 유효한 치료성을 갖는 신규 8-(저급알킬)비시클로[4.2.0] 옥탄 유도체
US5362751A (en) Tracheobronchodilator using 16-substituted PGEs
EP0402477B1 (en) Use of isocarbacyclins for preventing or treating organ diseases
CA1321544C (en) Use of glycerol ether ii
US4178385A (en) Method for treating hyperlipidemia in primates using 4-((4-fluorophenylmethyl)amino)benzoic acid
JPH0211514A (ja) スパガリン類製剤
EP0410646A2 (en) Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
TW201705952A (zh) 包含脂肪酸衍生物的醫藥組成物
KR830000677A (ko) 물질의 조성물